Contents

Search

rimonabant (Acomplia, Zimulti)

Tradename: Acomplia (withdrawn from European Market in 2009) Indications: 1) obesity [2] (see RIO-North America study) 2) smoking cessation 3) hypercholesterolemia 4) diabetes mellitus type 2 [5] Dosage: 5-20 mg QD Adverse effects: 1) depressed mood (< 4%) [7,9] 2) nausea (<4%) 3) anxiety (1%) [7,9] 4) headache (<1%) 5) seizures [6] Mechanism of action: 1) selective cannabinoid receptor 1 (CB1) antagonist 2) diminishes appetite 3) improves lipid profile 4) improves glycemic control 5) failed to reduce progression of coronary artery disease in patients with metabolic syndrome [8]

Interactions

drug adverse effects of anti-hyperlipidemic agents

Related

cannabinoid receptor 1; CB1; CB-R; CANN6 (CNR1, CNR) RIO-North America study

General

anorexiant (appetite suppressant) anti-hyperlipidemic agent

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 11(11): 2004 Investigational Drug: Rimonabant (Acomplia) Detail-Document#: 201114 (subscription needed) http://www.prescribersletter.com
  2. Journal Watch 25(12):98, 2005 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16;365(9468):1389-97. PMID: 15836887
  3. Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121-34. PMID: 16291982
  4. Prescriber's Letter 13(3): 2006 Acomplia (Rimonabant) and OTC Orlistat for Weight Loss Detail-Document#: 220313 (subscription needed) http://www.prescribersletter.com
  5. Sheen AJ et al, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006, 368:1660 PMID: 17098084
  6. Prescriber's Letter 14(7): 2007 (subscription needed) http://www.prescribersletter.com
  7. Christensen R et al, Efficacy and safety of the weight-loss drug remonant: A meta- analysis of randomised trials. Lancet 2007, 370:1706 PMID: 18022033
  8. Nissen SE et al, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRDIVARIUS randomized controlled trial. JAMA 2008, 299:1547 PMID: 18387931
  9. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 Nov 17;370(9600):1706-13. Review. Erratum in: Lancet. 2008 Feb 16;371(9612):558. PMID: 18022033